These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 6269423)

  • 1. Delta-9-tetrahydrocannabinol as an antiemetic.
    Anderson PO; McGuire GG
    Am J Hosp Pharm; 1981 May; 38(5):639-46. PubMed ID: 6269423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine.
    Sallan SE; Cronin C; Zelen M; Zinberg NE
    N Engl J Med; 1980 Jan; 302(3):135-8. PubMed ID: 6985702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. delta 9-Tetrahydrocannabinol (THC) as an antiemetic in patients treated with cancerchemotherapy; a double-blind cross-over trial against placebo.
    Kluin-Neleman JC; Neleman FA; Meuwissen OJ; Maes RA
    Vet Hum Toxicol; 1979 Oct; 21(5):338-40. PubMed ID: 516362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy.
    Sallan SE; Zinberg NE; Frei E
    N Engl J Med; 1975 Oct; 293(16):795-7. PubMed ID: 1099449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nabilone versus prochlorperazine for control of cancer chemotherapy-induced emesis in children: a double-blind, crossover trial.
    Chan HS; Correia JA; MacLeod SM
    Pediatrics; 1987 Jun; 79(6):946-52. PubMed ID: 3035479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic studies of delta-9-tetrahydrocannabinol in cancer patients.
    Frytak S; Moertel CG; Rubin J
    Cancer Treat Rep; 1984 Dec; 68(12):1427-31. PubMed ID: 6095996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antiemetic activity of tetrahydrocannabinol versus metoclopramide and thiethylperazine in patients undergoing cancer chemotherapy.
    Colls BM; Ferry DG; Gray AJ; Harvey VJ; McQueen EG
    N Z Med J; 1980 Jun; 91(662):449-51. PubMed ID: 6250106
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol (Delta 9-THC) on humans.
    Carlini EA
    Toxicon; 2004 Sep; 44(4):461-7. PubMed ID: 15302527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy.
    McCabe M; Smith FP; Macdonald JS; Woolley PV; Goldberg D; Schein PS
    Invest New Drugs; 1988 Sep; 6(3):243-6. PubMed ID: 2847994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of cannabinoids and their antiemetic effectiveness.
    Vincent BJ; McQuiston DJ; Einhorn LH; Nagy CM; Brames MJ
    Drugs; 1983 Feb; 25 Suppl 1():52-62. PubMed ID: 6301800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy. A comparison with prochlorperazine and a placebo.
    Frytak S; Moertel CG; O'Fallon JR; Rubin J; Creagan ET; O'Connell MJ; Schutt AJ; Schwartau NW
    Ann Intern Med; 1979 Dec; 91(6):825-30. PubMed ID: 517882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
    Müller-Vahl KR; Schneider U; Koblenz A; Jöbges M; Kolbe H; Daldrup T; Emrich HM
    Pharmacopsychiatry; 2002 Mar; 35(2):57-61. PubMed ID: 11951146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol.
    Cichewicz DL; Welch SP
    J Pharmacol Exp Ther; 2003 Jun; 305(3):812-7. PubMed ID: 12606610
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of the pharmacokinetics of high-dose cyclophosphamide and cisplatin by antiemetics.
    Cagnoni PJ; Matthes S; Day TC; Bearman SI; Shpall EJ; Jones RB
    Bone Marrow Transplant; 1999 Jul; 24(1):1-4. PubMed ID: 10435726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis.
    Joerger M; Wilkins J; Fagagnini S; Baldinger R; Brenneisen R; Schneider U; Goldman B; Weber M
    Drug Metab Lett; 2012 Jun; 6(2):102-8. PubMed ID: 22594565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant.
    Frakes LA; Brehm TL; Kosty MP; Miller WE; McMillan RL; Mason J; Meisenberg BR
    Bone Marrow Transplant; 1997 Sep; 20(6):473-8. PubMed ID: 9313880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetrahydrocannabinol as an antiemetic for cancer patients.
    Earhart RH; Buchanan-Davidson DJ
    Wis Med J; 1980 Mar; 79(3):47-8. PubMed ID: 6244707
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of cannabidiol and tetrahydrocannabinol on motion-induced emesis in Suncus murinus.
    Cluny NL; Naylor RJ; Whittle BA; Javid FA
    Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):150-6. PubMed ID: 18816298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.